However, the Pb-Cre;Ptenf/f GEMM, as a relatively benign prostate cancer model, does not allow CAMKK2 to be studied in the context of metastasis or progression to highly aggressive subtypes such as neuroendocrine prostate cancer (NEPC). The gene discussed is CAMKK2; the disease is prostate carcinoma.